MegaRobo, a Chinese company that builds robots capable of running physical experiments on their own, has raised $200 million in new funding to accelerate what it calls AI-for-science — a push to make laboratory work something AI agents can plan, execute, and interpret end to end. SiliconANGLE reported the funding on Thursday, noting the capital will go toward the company's core technology and the expansion of its automated life sciences infrastructure for increasingly complex physical systems.

Founded in 2016, MegaRobo sits at the intersection of two currents pulling on the industry at once: robotics that can act in the physical world, and AI models that can do more than answer questions. The company has now raised roughly $600 million to date, including a Series C of nearly $300 million in 2022, and its pitch has evolved from precision lab instruments to something closer to an operating system for automated discovery. For more on where the physical-AI funding wave is heading, see our roundup of the latest AI developments.

The investors behind the round

The round drew a mix of sovereign, regional, and strategic capital. Investors joining included Oman Investment Authority, Asia Investment Capital, Granite Asia, Sinovation Ventures, and CMB International, according to SiliconANGLE. The breadth of the syndicate — spanning the Gulf, Singapore-linked capital, and Chinese VC stalwarts — reflects how physical-AI and bio-automation startups are now raising at a scale that outgrows any single venture ecosystem.

Founder and chief executive Daniel Huang framed the thesis in a statement: "The first generation of AI learned from humanity's accumulated knowledge. The next generation will increasingly learn by acting in the physical world — through experiments, production and continuous feedback. That shift changes AI from a system that interprets the world into one that can help create new knowledge, materials, processes and products."

What Megalaxy Lab actually does

The company's flagship offering, Megalaxy Lab, is an AI-connected experimental platform. The idea, as MegaRobo describes it, is to make real-world experimentation programmable: researchers — or AI agents — configure an experiment, route it through automated laboratory systems, track execution, and receive structured, machine-readable results that feed directly into the next cycle of scientific reasoning.

That closing of the loop is the significant part. Most AI in science today assists with analysis or literature; Megalaxy is designed to let models propose and physically run experiments, then learn from the outcomes. MegaRobo also says the platform's large data readouts can be amplified as digital twins representing scientific data, protein design, biochemistry, and other properties — a simulation layer on top of the physical one.

Hardware with a decade of mileage

Unlike many AI-for-science entrants, MegaRobo's offering is anchored in hardware it has shipped for years. Its portfolio includes CellVue T2000, an automated cell-imaging instrument; the Auflo sample-preparation workstation; and the Seloris cell culturing automation system, alongside the precision measurement and inspection tools it sells to manufacturers. SiliconANGLE characterizes Megalaxy Lab as the public face of the company's AI-for-science strategy, with the instruments representing the concrete equipment it builds for industry.

The company is also developing what it calls the One Intelligence Stack — described as a common technology foundation spanning instruments, machines, materials processes, and real-world feedback. The framing positions it less as a collection of AI products and more as infrastructure that lets AI act, learn, and observe across complex physical environments.

Poreva Open: testing protein design against real wet labs

The most concrete evidence of the strategy is Poreva Open, a global AI protein design challenge MegaRobo is running with industry partners including Tencent Cloud and Twist Bioscience. The challenge is open to all models and technical approaches, and Megalaxy will provide wet-lab validation for more than 10,000 protein design sequences — giving model developers a chance to test their designs against real experimental data rather than benchmarks alone.

That matters because protein design has become one of the most competitive showcases for AI in biology, and the field's persistent weakness is ground truth: models can generate plausible structures, but verifying them requires scarce laboratory capacity. A robotics lab offering standardized wet-lab validation at that scale is effectively selling the missing half of the loop.

Physical AI's funding wave

MegaRobo's raise lands amid a broader surge of capital into robots that learn by doing. SiliconANGLE's coverage this month has tracked several major rounds in the space, including Paris-based Genesis AI's $500 million Series A at a $3.5 billion valuation for its wheeled general-purpose robot, and Agile Robots' $500 million funding round led by SoftBank at an $8.5 billion valuation. The common thread is a bet that the next tranche of AI capability comes from closing the loop between models and the physical world — whether that loop is a factory floor, a home, or a biology lab.

MegaRobo's variant of the bet is narrower and, arguably, nearer to revenue: laboratories are structured environments with high-value outputs, where automation has an established budget line and AI agents have an obvious role in experiment design. The company says the new capital will fund additional hiring of AI researchers and roboticists and expand its training data collection to grow its models' capabilities.

If the physical-AI thesis holds, the labs that run science may become as strategically important as the models that design it — and MegaRobo now has another $200 million to prove that out.

---

Stay Ahead of AI

Get the latest AI news, analysis, and breakthroughs — all in one place.

Read more AI news →